ACQUISITIONS (Tables)

9 Months Ended

Jul. 31, 2020

Business Combinations [Abstract]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The following table summarizes the allocation of the purchase price to the estimated fair values of the assets acquired and liabilities assumed on the closing date of August 23, 2019 (in millions):

Cash and cash equivalents		$	10
Accounts receivable		28
Inventories		21
Other current assets		2
Property, plant and equipment		8
Intangible assets		641
Goodwill		483
Total assets acquired	1,193
Accounts payable		(4		)
Deferred revenue		(5		)
Employee compensation and benefits		(7		)
Other accrued liabilities		(2		)
Long-term debt		(4		)
Net assets acquired		$	1,171

Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination

The components of intangible assets acquired in connection with the BioTek acquisition were as follows (in millions):

	Fair Value			Estimated Useful Life
Developed product technology		$	387	5-13 years
Customer relationships		202		3-8 years
Backlog		5		2 months
Tradenames and trademarks		43		10 years
Total intangible assets subject to amortization		637
In-process research and development		4
Total intangible assets		$	641

Pro Forma Information

The following represents the unaudited proforma operating results as if BioTek and ACEA had been included in the company's condensed consolidated statements of operations as of the beginning of fiscal 2018 (in millions, except per share amounts):

	Three Months Ended July 31,		Nine Months Ended July 31,
	2019		2019
Net revenue	$	1,319	$	3,930
Net income	$	174	$	816
Net income per share — basic	$	0.56	$	2.58
Net income per share — diluted	$	0.55	$	2.55